Technical Analysis for STML - Stemline Therapeutics, Inc.

Grade Last Price % Change Price Change
grade D 15.15 0.00% 0.00
STML closed unchanged on Friday, August 17, 2018, on 67 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions.

Trend Table & Recent Alerts
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Down Down Up
See historical STML trend table...

Date Alert Name Type % Chg
Aug 17 NR7 Range Contraction 0.00%
Aug 15 Earnings Movers Other -0.33%
Aug 14 200 DMA Resistance Bearish -1.62%
Aug 14 Shooting Star Candlestick Bearish -1.62%
Aug 14 Non-ADX 1,2,3,4 Bearish Bearish Swing Setup -1.62%
Aug 14 Earnings Movers Other -1.62%
Aug 13 Non-ADX 1,2,3,4 Bearish Bearish Swing Setup 0.00%
Aug 13 Outside Day Range Expansion 0.00%
Aug 10 Shooting Star Candlestick Bearish 1.34%
Aug 10 MACD Bullish Signal Line Cross Bullish 1.34%

Older signals for STML ...

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
Stemline Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing proprietary therapeutics that target cancer stem cells (CSCs) and tumor bulk. It develops StemScreen platform technology consisting of StemScreen-1 and StemScreen-2 for the identification of novel CSC-directed compounds. The company is developing SL-401, a biologic-drug conjugate, which has completed Phase I/II clinical trial for relapsed or refractory acute myeloid leukemia; and SL-701, a synthetic peptide vaccine that has completed two Phase I/II clinical trials for pediatric and adult high-grade gliomas. Its products under preclinical stage include SL-301, a small molecule gamma-secretase inhibitor that inhibits Notch, a pathway expressed by CSCs and tumor bulk of multiple cancer types; SL-101, a mAb-based compound that targets CD123; SL-201, a small molecule active against certain hematologic and solid tumor types; and SL-601, mAb-based compound that targets a cell surface marker on bladder CSCs. The company also in-licensed intellectual property directed to mAb-based therapeutics to validated oncology targets, including Glypican-3, Tie-1, CD133, Frizzled, Smoothened, and Patched. Stemline Therapeutics, Inc. was founded in 2003 and is based in New York, New York.
Is STML a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 20.55
52 Week Low 7.65
Average Volume 194,630
200-Day Moving Average 16.0963
50-Day Moving Average 16.2435
20-Day Moving Average 15.1775
10-Day Moving Average 14.91
Average True Range 0.714
ADX 20.77
+DI 17.0552
-DI 21.5771
Chandelier Exit (Long, 3 ATRs ) 14.958
Chandelier Exit (Short, 3 ATRs ) 16.047
Upper Bollinger Band 16.5404
Lower Bollinger Band 13.8146
Percent B (%b) 0.49
BandWidth 17.959479
MACD Line -0.3572
MACD Signal Line -0.4824
MACD Histogram 0.1252
Fundamentals Value
Market Cap 355.34 Million
Num Shares 23.5 Million
EPS -2.47
Price-to-Earnings (P/E) Ratio -6.13
Price-to-Sales 202.21
Price-to-Book 3.03
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 15.75
Resistance 3 (R3) 15.72 15.48 15.65
Resistance 2 (R2) 15.48 15.33 15.50 15.62
Resistance 1 (R1) 15.32 15.24 15.40 15.35 15.58
Pivot Point 15.08 15.08 15.13 15.10 15.08
Support 1 (S1) 14.92 14.93 15.00 14.95 14.72
Support 2 (S2) 14.68 14.84 14.70 14.68
Support 3 (S3) 14.52 14.68 14.65
Support 4 (S4) 14.55